FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. A monoclonal antibody specifically binding CD47 has been proposed. A pharmaceutical composition including this antibody is also proposed for the prevention and treatment of solid and hematological types of cancer.
EFFECT: invention provides blocking of the interaction between CD47 and its SIRP alpha ligand and can be used in cancer therapy in a human patient.
13 cl, 36 dwg, 3 tbl, 11ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| OBTAINING MULTISPECIFIC MIXTURES OF ANTIBODIES AND METHODS OF USE THEREOF | 2018 |
|
RU2815826C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
